Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by an educational grant from AstraZeneca.
Salon Ballroom A, Sections 1 & 2, Lower Level
720 S Michigan Avenue
Chicago, IL 60605
There has been a recent deluge of pre-clinical and clinical data pertaining to the potential applications of poly (ADP-ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer. It is crucial for clinicians who treat patients with breast cancer to have a solid understanding of the mechanistic rationale for the use of these medications, in order to optimize their potential application. It is also important for clinicians to be aware of methods that may help to optimize patient selection for potential PARP inhibitor therapy and personalize breast cancer treatment approaches. There are lessons that may be drawn from the clinical data and experience with PARP inhibitor use in the treatment of ovarian cancer; however, there are distinctions that need to be made regarding the application of these lessons to patients with breast cancer. The Medical Crossfire® format of this symposium will feature leading experts in management of patients with breast cancer who will address multiple topics pertaining to the use of PARP inhibitors in the treatment of patients with breast cancer through a combination of didactic presentation and panel discussion. The program will conclude with a discussion of data presented at the 2017 ASCO Annual Meeting, and a question and answer session to allow participants to interact with the faculty to discuss challenges seen in their own practice settings.
This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer will be invited to participate.
After successful completion of this educational activity, participants should be able to:
Mark E. Robson, MD
Attending Physician, Clinical Genetics and Breast Medicine Services
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018